Predictors of vascular disease in myelodysplastic syndromes. Issue 2 (28th September 2020)

• Record Type: Journal Article
• Authors: Faber, Mark G.; Lloyd, David R.; Singh, Abhay; Baron, Jeffrey; Przespolewski, Amanda; Griffiths, Elizabeth A.; Wang, Eunice S.; Thota, Swapna
• Is Part Of: EJHaem. Volume 1:Issue 2(2020)
• Page Start: 467
• Page End: 472
• Publication Date: 2020-09-28
• Subjects: atherosclerosis -- hematopoiesis -- myelodysplastic syndrome; Hematology -- Periodicals; 616.15
• DOI: 10.1002/jha2.101
• Languages: English
• ISSNs: 2688-6146

Abstract

Abstract: The escalating link between somatic mutations commonly seen in myelodysplastic syndromes (MDS) and atherosclerotic vascular disease has increased the interest in management and associations of these conditions. We present a retrospective study examining clinical and molecular variables associated with vascular disease in patients with MDS. This study included a comprehensive evaluation of 236 patients with MDS. Our study has multiple findings. Mutations in ASXL1 correlated with increased risk of vascular disease for the entire cohort ( P = .013). Though this has been replicated in other studies, there are no guidelines at this time for preventing vascular events in these patients. Our study also showed that lower ferritin levels may be linked to increased vascular events ( P = .043), therefore the optimal use of supportive red blood cell transfusions in patients with MDS and the overall impact of inflammatory markers such as erythrocyte sedimentation rate and c‐reactive protein should be re‐addressed. Furthermore, our study showed that patients with Trisomy 8 in the low‐risk MDS cohort (based on IPSS‐R scores) were protected from vascular events ( P = .036). Our findings of lower ferritin being linked with increased risk of vascular events as well as patients with Trisomy 8 being protected from vascular events may impact patient care. There do not appear to be any prior studies with these findings. In addition, given the connection between MDS and atherosclerotic vascular disease, we believe guideline‐based management of cardiac risk factors among MDS patients may improve overall outcomes. Further studies with larger patient cohorts are needed to further investigate these findings.